GTBP (GT Biopharma) Cyclically Adjusted Book per Share: $-960.09 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GTBP GT Biopharma Inc GTBP
21 GF Score
Price $0.28
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Cyclically Adjusted Book per Share?

GT Biopharma GTBP +2.11% 21 Cyclically Adjusted Book per Share is $-960.09 as of Jun. 2026. GuruFocus rates GTBP with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

GT Biopharma's adjusted book value per share for the three months ended in Jun. 2026 was $0.080. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-960.09 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -2.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -58.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of GT Biopharma was 4.00% per year. The lowest was -717.40% per year. And the median was -5.50% per year.

As of today (2026-08-19), GT Biopharma's current stock price is $0.2812. GT Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $-960.09. GT Biopharma's Cyclically Adjusted PB Ratio of today is .


GT Biopharma  (NAS:GTBP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


GT Biopharma Cyclically Adjusted Book per Share Related Terms


GT Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Cyclically Adjusted Book per Share Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -807.17 -857.51 -885.15 -909.83 -932.13

GT Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -928.88 -934.98 -932.13 -949.56 -960.09

GTBP vs GDTC, KALA, INAB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, GT Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cyclically Adjusted PB Ratio falls into.


GTBP
21GF Score
GT Biopharma Inc GTBP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GT Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.08/333.9520*333.9520
=0.080

Current CPI (Jun. 2026) = 333.9520.

GT Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201609 -6.857 241.428 -9.485
201612 -7.548 241.432 -10.440
201703 -17,944.000 243.801 -24,579.205
201706 -19,918.000 244.955 -27,154.604
201709 2,590.663 246.819 3,505.229
201712 2,569.959 246.524 3,481.377
201803 2,575.755 249.554 3,446.863
201806 2,512.541 251.989 3,329.781
201809 137.551 252.439 181.966
201812 116.535 251.233 154.904
201903 100.822 254.202 132.453
201906 88.757 256.143 115.719
201909 -138.321 256.759 -179.906
201912 -139.737 256.974 -181.596
202003 -149.920 258.115 -193.968
202006 -184.831 257.797 -239.431
202009 -194.954 260.280 -250.136
202012 -169.172 260.474 -216.894
202103 35.358 264.877 44.579
202106 38.869 271.696 47.775
202109 31.508 274.310 38.359
202112 20.495 278.802 24.549
202203 16.501 287.504 19.167
202206 15.092 296.311 17.009
202209 14.717 296.808 16.559
202212 10.754 296.797 12.100
202303 10.620 301.836 11.750
202306 8.680 305.109 9.501
202309 7.244 307.789 7.860
202312 5.413 306.746 5.893
202403 3.846 312.332 4.112
202406 2.465 314.175 2.620
202409 0.938 315.301 0.993
202412 -0.748 315.605 -0.791
202503 -0.387 319.799 -0.404
202506 0.874 322.561 0.905
202509 0.496 324.800 0.510
202512 0.227 324.054 0.234
202603 0.215 330.213 0.217
202606 0.080 333.952 0.080

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $-960.09 mean?
GT Biopharma (GTBP) has a Cyclically Adjusted Book per Share of $-960.09 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Cyclically Adjusted Book per Share too high?
GT Biopharma's current Cyclically Adjusted Book per Share is $-960.09. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Cyclically Adjusted Book per Share compare to GDTC and KALA?
GT Biopharma's Cyclically Adjusted Book per Share of $-960.09 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on GT Biopharma and its competitors. GT Biopharma's current Cyclically Adjusted Book per Share is $-960.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (GTBP) has a current Cyclically Adjusted Book per Share of $-960.09. The current Cyclically Adjusted Book per Share is $-960.09. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For GT Biopharma (GTBP), the current Cyclically Adjusted Book per Share is $-960.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for GTBP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price